Predictive significance of FGFR4 p.G388R polymorphism in metastatic colorectal cancer patients recei...
Predictive significance of FGFR4 p.G388R polymorphism in metastatic colorectal cancer patients receiving trifluridine/tipiracil (TAS-102) treatment
About this item
Full title
Author / Creator
Ottaiano, Alessandro , Santorsola, Mariachiara , Ianniello, Monica , Ceccarelli, Anna , Casillo, Marika , Sabbatino, Francesco , Petrillo, Nadia , Cascella, Marco , Caraglia, Francesco , Picone, Carmine , Perri, Francesco , Sirica, Roberto , Zappavigna, Silvia , Nasti, Guglielmo , Savarese, Giovanni and Caraglia, Michele
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
TAS-102 (Lonsurf
) is an oral fluoropyrimidine consisting of a combination of trifluridine (a thymidine analog) and tipiracil (a thymidine phosphorylation inhibitor). The drug is effective in metastatic colorectal cancer (mCRC) patients refractory to fluorouracil, irinotecan and oxaliplatin. This study is a real-world analysis, investigating the...
Alternative Titles
Full title
Predictive significance of FGFR4 p.G388R polymorphism in metastatic colorectal cancer patients receiving trifluridine/tipiracil (TAS-102) treatment
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_0cb75c489e0747b7a5a221e4b1270d45
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_0cb75c489e0747b7a5a221e4b1270d45
Other Identifiers
ISSN
1479-5876
E-ISSN
1479-5876
DOI
10.1186/s12967-024-05184-w
